Clinical Trials Sponsored by Guangzhou Henovcom Bioscience Co. Ltd.

Total 646 results

Guangzhou Henovcom Bioscience Co. Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Parkinson's Disease

United States
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

IPF

United States
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Healthy

United States
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Guangzhou Henovcom Bioscience Co. Ltd.
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

Completed

A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Influenza

China
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Solid Tumor

China
Creative Biosciences (Guangzhou) Co., Ltd.

Completed

A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China

Neoplasms | Colorectal Neoplasms | Colorectal Cancer | Digestive System Neoplasm | Advanced Adenocarcinoma | Hyperplastic Polyp

China
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Persistent, Recurrent, or Metastatic Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Creative Biosciences (Guangzhou) Co., Ltd.
Guangzhou Xiangkang Medical Research Co., Ltd.

Completed

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Pneumonia | Adenocarcinoma | Small Cell Lung Cancer | Chronic Obstructive Pulmonary Disease | Non-Small Cell Lung Cancer | Lung Cancer | Tuberculosis | Chronic Bronchitis | Squamous Cell Carcinoma | Lung Neoplasm | Respiratory Tract Infection | Acute Bronchitis | Adenosquamous Carcinoma | Large Cell Carcinoma | Sarcomatoid... and other conditions

China
Creative Biosciences (Guangzhou) Co., Ltd.
Guangzhou Xiangkang Medical Research Co., Ltd.

Recruiting

A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China

Bladder Cancer | Urothelial Carcinoma | Urocystitis | Urinary Bladder Stone

China
Hangzhou Sciwind Biosciences Co., Ltd.

Recruiting

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

RSV Infection

China
Hangzhou Sciwind Biosciences Co., Ltd.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Type 2 Diabetes Mellitus | T2DM

China
Hangzhou Sciwind Biosciences Co., Ltd.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Weight Management

China
Hangzhou Sciwind Biosciences Co., Ltd.

Recruiting

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Healthy Volunteers

China
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Phase Ia Study of XW001 in Healthy Adult Subjects

Respiratory Syncytial Virus Infections

China
Hangzhou Sciwind Biosciences Co., Ltd.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus | T2DM

China
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (XW003)

Obesity | Type 2 Diabetes Mellitus | Nonalcoholic Steatohepatitis

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Not yet recruiting

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Obesity | Type 2 Diabetes Mellitus

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Obesity

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.; Sciwind Biosciences USA Co., Ltd.

Withdrawn

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

COVID-19 Acute Respiratory Distress Syndrome

Argentina, Peru
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Creative Biosciences (Guangzhou) Co., Ltd.
Dongguan Shipai Hospital

Completed

Retrospective Analysis of Colorectal Cancer Screening Results

Neoplasms | Colorectal Neoplasms | Colorectal Cancer | Digestive System Neoplasm | Advanced Adenocarcinoma | Hyperplastic Polyp

China
Sun Yat-sen University
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
Hangzhou YuYuan Bioscience Technology Co., Ltd.
LG Chem

Completed

Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women.

Infertility, Female

China
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP615 in Healthy Female

Cervical Cancer

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Guangzhou Institute of Respiratory Disease
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Hyperlipidemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China

Clinical Trials Sponsored by Guangzhou Henovcom Bioscience Co. Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations